We currently manufacture seven products in three dosage forms for Ceclor in Eddingpharm (Suzhou) Co., Ltd. ， which occupies approximately 30,000 square meters with a total gross floor area of 9,261 square meters.The whole production process is carefully designed to ensure maximum quality of products and Six Sigma (6σ) quality level.

Our highly automated production lines in our Ceclor manufacturing facility consistently screen out and discard in-process or semi-finished products that fail to meet certain criteria during the production process.

We are developing a state-of-the-art research and development center for respiratory medicines located in Suzhou. In 2019, our Edding respiratory research and development center passed its on-site inspection and obtained the drug manufacturing license issued by NMPA. We apply our robust proprietary quality management systems to ERC, ensuring high quality standards and facilitating the drug development process. 

We are building two inhalation technology platforms for nebulizer suspension and DPI drugs. The technology for the manufacturing of FPN was transferred to us in 2022. In the same year, we completed construction of the manufacturing facility for FPN and submitted manufacturing application to the NMPA. Our manufacturing facility for FPN passed on-site inspection in January 2023, and the commercial production of FPN was successfully achieved in March 2024.

We manage an end-to-end global supply chain covering Europe, the U.S. and Australia for our core commercialized products, reflecting our cross-regional supply chain management and coordination capabilities. After our acquisition of these products in China, we continue to engage the original suppliers and CMOs for key APIs, raw materials and/or finished products.